Rx Approval Times Depend On Amount, Not Source, Of FDA Funds, Study Says
Executive Summary
Drug approval times are affected by the amount of funding but not the source of funds, a study published in Health Affairs finds
You may also be interested in...
Rx Withdrawals: FDA, GAO Differ On Whether Recent Increase Is “Real”
The prescription drug withdrawal rate has not shown a "real" increase since the implementation of the Prescription Drug User Fee Act, FDA declared in response to a Government Accounting Office report
FDA Considering Lotronex Risk Management Advisory Cmte. Meeting For July
FDA is considering another advisory committee meeting for GlaxoSmithKline's Lotronex to discuss potential risk management options that would allow renewed use of the irritable bowel syndrome agent.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011